Matricelf Reports Statistically Significant Motor Function Improvement in Preclinical Efficacy Study of Chronic Spinal Cord Injury

Ness Ziona, Israel--(Newsfile Corp. - November 5, 2026) - Matricelf Ltd. (TASE: MTLF), a biotechnology company developing personalized engineered neural tissue for spinal cord injury, today announced positive results from its comprehensive preclinical efficacy study, demonstrating statistically significant improvements in motor function following transplantation of its engineered human neural tissue. The tr

2026-11-05 11:31 AM EST

Get News by Email

Analyst, journalist, or company stakeholder? Sign up to receive news releases by email for Matricelf Ltd. or all companies in the Biotechnology, Health industry.

Stock Quote

Financial Market Data copyright © 2023 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

RSS Feeds

Our last 10 news releases for Matricelf Ltd. in RSS format are available for public consumption. Full text RSS feeds which can be categorized by type and industry are available upon request.

Ready to Announce with Confidence?

Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Matricelf Ltd.

Matricelf is a biotechnology company developing personalized regenerative therapies for spinal cord injury. Its investigational approach combines patient derived cells and biological material to create engineered neural tissue intended for transplantation into the injured spinal cord.

Recent News

Matricelf Reports Statistically Significant Motor Function Improvement in Preclinical Efficacy Study of Chronic Spinal Cord Injury

Ready to Announce with Confidence?